FDA Registration vs. FDA Approval: What Your Device Listing Actually Certifies

FDA Registration Is Not FDA Approval -- And Confusing the Two Can Cost You Everything

It happens more often than it should. A startup founder secures their FDA Establishment Registration and Device Listing, prints out the confirmation, and starts telling investors and customers their device is FDA approved. It feels like a milestone -- because it is one. But it is not the milestone they think it is.

This misunderstanding is not just a marketing problem. It is a regulatory exposure problem. Misrepresenting a device as FDA approved when it has only been registered and listed can trigger Warning Letters, import alerts, and untitled letters from the Office of Regulatory Affairs. In the worst cases, it becomes material misrepresentation to investors -- a legal problem that extends well beyond FDA jurisdiction.

Let us be direct about what registration and listing actually do, what they do not do, and what you actually need before you can lawfully market your device in the United States.

What FDA Establishment Registration Actually Is

Under 21 CFR Part 807, manufacturers, distributors, and importers of medical devices are required to register their establishments with FDA annually. This is an administrative process. You provide your facility information, pay the applicable annual registration fee (set each fiscal year by FDA under MDUFA authority), and your establishment appears in FDA's public database.

Registration tells FDA where you are. That is essentially it. It does not mean FDA has reviewed your device, evaluated your quality system, inspected your facility, or determined that your product is safe and effective. FDA does not issue a registration number as a form of endorsement. The agency itself is explicit on this point -- FDA's own website states that registration and listing does not mean FDA has approved or cleared the device.

What Device Listing Under 21 CFR 807.20 Actually Certifies

Device listing, governed by 21 CFR 807.20 through 807.39, requires that you identify each device you market commercially in the United States. You submit the device name, product code, and the premarket submission number -- if one exists and is required.

Here is the critical nuance: listing a device does not certify that the device is legally on the market. It does not confirm that you have obtained the required premarket authorization. FDA uses listing data for surveillance, inspections, and enforcement prioritization -- not as a gate that validates your device's legal status.

If you are required to submit a 510(k) under Section 510(k) of the Federal Food, Drug, and Cosmetic Act and you list your device without doing so, you have simply documented your noncompliance in FDA's own system.

The Three Pathways That Actually Authorize U.S. Market Access

Registration and listing are prerequisites for marketing -- they are not authorization to market. That authorization comes through one of three primary pathways:

• 510(k) Clearance: For Class II devices (and some Class I), you demonstrate substantial equivalence to a legally marketed predicate device. FDA issues a clearance letter -- this is the document that permits marketing. The language is critical: the device is cleared, not approved.
• Premarket Approval (PMA): Required for most Class III devices, PMA involves a full scientific and regulatory review of valid scientific evidence demonstrating reasonable assurance of safety and effectiveness. PMA devices are approved -- this is the one context where the word approval is technically correct.
• De Novo Classification: For novel low-to-moderate risk devices without a predicate, De Novo provides a pathway to establish a new device type and receive marketing authorization. De Novo granted devices are authorized, not cleared or approved in the traditional sense.

Devices that are Class I exempt -- those that fall under the exemptions listed in 21 CFR Parts 862 through 892 -- may not require premarket submission, but they still require registration and listing, and they must comply with applicable General Controls under 21 CFR Part 820 and Part 801.

Where Founders and Small Companies Get Into Trouble

The most common regulatory missteps we see at ADB Consulting and CRO Inc. fall into a predictable pattern:

• Completing registration and listing and assuming that constitutes market authorization for a device that actually requires a 510(k)
• Using the term FDA registered in sales and marketing materials in a way that implies FDA approval or safety endorsement
• Listing a device under an incorrect product code that underrepresents its risk classification, effectively disguising a Class II device as an exempt Class I
• Failing to update listings when devices are modified in ways that could trigger a new 510(k) obligation under 21 CFR 807.81(a)(3)

Each of these scenarios carries real enforcement risk. FDA's Office of Regulatory Affairs conducts surveillance queries on listed devices and cross-references them against cleared and approved products. The gaps are findable -- and they are found.

What Your Registration Confirmation Should Represent

Your FDA Establishment Registration and Device Listing confirmation represents one thing cleanly: that you have met your administrative obligation to notify FDA of your existence and your device portfolio. It is the regulatory equivalent of a business license. Necessary, but not sufficient.

The documentation that actually represents your device's legal market status is your 510(k) clearance letter, your PMA approval order, your De Novo authorization letter, or your documented determination that your device qualifies for a recognized exemption -- with the regulatory citations to support it.

If you cannot point to one of those documents, you do not yet have market authorization.

Getting This Right Before It Becomes a Problem

FDA registration and listing compliance seems straightforward until it is not. Product code selection, classification determination, predicate identification, and the timing of listing relative to premarket submissions all require careful analysis. Getting the classification wrong at the listing stage creates a paper trail that can complicate enforcement discussions later.

At ADB Consulting and CRO Inc., we work with medical device startups and small-to-mid-size companies to build regulatory strategies that are accurate, defensible, and aligned with FDA's current thinking. That means getting registration and listing right -- and making sure it is backed by the premarket authorization your device actually requires.

If you are unsure whether your current registration and listing status reflects your true regulatory position, or if you are preparing for your first market entry and want to get it right from the start, we are ready to help.

Book a free discovery call with Andre Butler at ADB Consulting and CRO Inc. Visit adbccro.com to schedule your session. Bring your device description, your intended use, and your questions -- we will cut through the confusion and give you a clear regulatory roadmap.

If this applies to your program, our Device Registration service walks through the process in detail.